Stay updated with breaking news from Amyt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Political environment that resembles ours i p in so my ways except there s less free speech there is more police involvement in politics. w brazil is what america will be very soon if we don t slowwn this down. we re here at the presidential palace h because we told you a minute ago we just sat downth with the president of brazil, president bush, full scenario ahead of an election here that will have an effect on the entire hemisphere, very much including the united statese hnclu. here s part of i our conversation. the parallels between politicsbe in brazil and politics in the united statess are striking to an american. you are opposed by aayo coalitin of billionaires, college professors and cnn. tell us what the opposition wants. what will brazil look likeet ift your opponent wins? pr et i mean, i myself with myt election itself was almost a miracle. i had nothing going for me. i was just an isolated memberbe of congress. me ....
Amryt Pharma plc (NASDAQ:AMYT – Get Rating) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 138,100 shares, an increase of 78.9% from the April 30th total of 77,200 shares. Based on an average daily volume of 141,900 shares, the short-interest ratio is […] ....
Amryt Pharma plc (NASDAQ:AMYT – Get Rating) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 138,100 shares, an increase of 78.9% from the April 30th total of 77,200 shares. Based on an average daily volume of 141,900 shares, the short-interest ratio is […] ....
Amryt Pharma (NASDAQ:AMYT – Get Rating) released its earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.03), MarketWatch Earnings reports. Amryt Pharma had a negative net margin of 6.91% and a positive return on equity of 4.06%. During the same period […] ....
Amryt Pharma (NASDAQ:AMYT – Get Rating) had its target price boosted by SVB Leerink from $9.00 to $10.00 in a research note published on Thursday morning, MarketBeat.com reports. They currently have an outperform rating on the stock. SVB Leerink also issued estimates for Amryt Pharma’s Q4 2022 earnings at ($0.01) EPS. Other equities analysts have […] ....